Pair Name	Scutellarin, Cisplatin
Disease Info	[ICD-11: 2C73]	Ovarian cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	OVCAR-3	High grade ovarian serous adenocarcinoma	Homo sapiens (Human)	CVCL_0465
	SK-OV-3	Ovarian serous cystadenocarcinoma	Homo sapiens (Human)	CVCL_0532
Result	Our study supports that scutellarin acts as a potential sensitizer to cisplatin treatment and the combination of scutellarin and cisplatin may be a novel therapeutic strategy to overcome platinum resistance of ovarian cancer.

Pair Name	Scutellarin, Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis and autophagy
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Expression	MAP1LC3A	hsa84557
	Up-regulation	Phosphorylation	MAPK1	hsa5594
	Up-regulation	Phosphorylation	MAPK3	hsa5595
	Down-regulation	Expression	MET	hsa4233
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
	PC-9	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_B260
	NCI-H1975	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_1511
In Vivo Model	A549/DDP-Luc cells (4×10⁶) were subcutaneously injected into the right flank of 4-to-6 week-old female BALB/c nude mice.
Result	This study identifies the unique role of scutellarin in reversing cisplatin resistance through apoptosis and autophagy, and suggests that combined cisplatin and scutellarin might be a novel therapeutic strategy for patients with NSCLC.